Andrew Hedin

Andrew Hedin is a Venture Capital Investor and Peptone board member focused on biotechnology therapeutics, healthcare software, and services. A partner at Bessemer’s Cambridge office, he previously invested in biotechnology and digital health at F-Prime Capital and advised biopharma clients at Leerink Partners; he holds an MBA from Wharton and studied biological basis of behavior at the University of Pennsylvania.